Fortrea Holdings Inc. (FTRE)

Clinical trials contractor, half in Asia-Pacific. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 26, 2026. Ranked 85 of the 95 Healthcare companies read so far, by the share within reach now.

The filing states 14,300 employees in about 100 countries, 47% in Asia-Pacific, running clinical trials for biopharma customers, so one research pattern carries the workforce.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 17% now, 42% at the end of 2027, 57% at the end of 2028, 66% at the end of 2030. By the patterns, the work is about 67% desk work, 17% people work and 16% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 33% of the working time stays with people (conversation, in-person and hands-on work), 51% becomes checking a model's work and 6% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

14,300 employees as of December 31, 2025 (stated). Not stated alone; 26% of employees are in the Americas, 27% in EMEA and 47% in Asia-Pacific.

The filing: “Fortrea's approximately 14,300 employees are strategically balanced throughout the world, with employee breakdown by region of: 26% in the Americas, 27% in EMEA, and 47% in Asia-Pacific.”

The workforce as industry patterns

What the filing says about the workforce: About 14,300 in about 100 countries; 26% Americas, 27% EMEA, 47% Asia-Pacific; 97% full-time and 3% part-time; about 69% female globally and 60% of management; headcount 18,000 in 2023 and 15,500 in 2024, as the filing's history shows.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Scientific Research and Development Services, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• IQVIA Holdings Inc. (IQV, 93,000 employees)22% now, 62% by 2028
• Charles River Laboratories International, Inc. (CRL, 19,700 employees)17% now, 55% by 2028

What the filing says about AI

35 sentences in the filing name AI. Thirty-five sentences: the company says it is investing in AI, machine learning and workflow automation to speed and improve clinical research, using AI-enabled tools in its commercial work, and has added AI learning and digital literacy training for employees.

• “We are making focused investments in artificial intelligence ("AI"), machine learning ("ML"), other advanced technologies, and workflow automation and orchestration to drive speed, agility, quality and enhanced patient safety in clinical research.”
• “Over the past decade, we have seen the biopharma industry leverage science, technology, and AI to advance the level of understanding of the pathogenesis of human disease, and to identify new therapeutic targets and treatments.”
• “We are working to leverage data, analytics and AI-enabled tools to support the identification, targeting and qualification of prospects; bring the right expertise into early engagement with customers; tailor and sharpen our value propositions; upskill our commercial and account management teams; increase senior management engagement with customers; and focus on consistently delivering.”
• “Selective Investment in Technology, Data and Application of Artificial Intelligence (AI) for Speed and Simplification Fortrea takes a focused, digital-led approach to technology, investing selectively in platforms, data assets, AI, ML, other advanced technologies, workflow automation and orchestration that accelerate trial execution and drive quality and simplification across clinical development.”
• “The use of AI, ML and other advanced technologies in clinical research is still relatively early in adoption, but promises further improvement in study design, site selection, patient recruitment and engagement, and streamlining of operational processes. 11 Table of Contents Fortrea integrates its in-house datasets, those from strategic data partners and a broad range of additional third partie...”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 202319median 1
• Fiscal 202427median 4
• Fiscal 202535median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The patterns stand for work in Asia-Pacific and EMEA under rule 7, the same clinical research work; the U.S. share is not stated alone.
• No count by function: one pattern by description (c).

Source: the company's annual report on EDGAR, accession 0001628280-26-012244, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.